公开(公告)号：WO2008005814A2

公开(公告)日：2008-01-10

申请号：PCT/US2007/072430

申请日：2007-06-29

Applicant: ABBOTT LABORATORIES ,  ABBOTT GMBH & CO. KG ,  SOGIN, David C. ,  SAFER, Anton ,  SMYTH, Brendan J.

Inventor： SOGIN, David C. ,  SAFER, Anton ,  SMYTH, Brendan J.

IPC: A61B5/103

CPC classification number: C12Q1/485 ,  A61B5/021 ,  A61B5/0285 ,  A61B5/4884 ,  G01N2333/71 ,  G01N2800/321 ,  G01N2800/368

Abstract: A method is provided that allows a subject to be diagnosed as having one of a variety of hypertensive states, including pre-eclampsia, based on the measurement of a plurality of factors including the level of soluble fms-like tyrosine kinase 1 (sFlt-1), an obesity factor and optionally one or more additional factors, which may be physiological parameters or biomarkers. The method can be used to determine hypertensive states associated with pregnancy, or associated with anti-angiogenic drug therapy. The method is thus useful for diagnosing the hypertensive status of pregnant women, as well as patients undergoing anti-angiogenic treatment (e.g., chemotherapy).

Abstract translation: 提供了一种方法，其允许受试者被诊断为具有多种高血压状态之一，包括先兆子痫，基于多种因素的测量，包括可溶性fms样酪氨酸激酶1（sFlt-1 ），肥胖因子和任选的一个或多个另外的因子，其可以是生理参数或生物标志物。 该方法可用于确定与怀孕相关的高血压状态，或与抗血管生成药物治疗相关。 因此，该方法可用于诊断孕妇以及进行抗血管生成治疗（例如化疗）的患者的高血压状态。

公开(公告)号：WO2008005814A3

公开(公告)日：2008-07-31

申请号：PCT/US2007072430

申请日：2007-06-29

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG ,  SOGIN DAVID C ,  SAFER ANTON ,  SMYTH BRENDAN J

Inventor： SOGIN DAVID C ,  SAFER ANTON ,  SMYTH BRENDAN J

IPC: A61B5/00

CPC classification number: C12Q1/485 ,  A61B5/021 ,  A61B5/0285 ,  A61B5/4884 ,  G01N2333/71 ,  G01N2800/321 ,  G01N2800/368

Abstract: A method is provided that allows a subject to be diagnosed as having one of a variety of hypertensive states, including pre-eclampsia, based on the measurement of a plurality of factors including the level of soluble fms-like tyrosine kinase 1 (sFlt-1), an obesity factor and optionally one or more additional factors, which may be physiological parameters or biomarkers. The method can be used to determine hypertensive states associated with pregnancy, or associated with anti-angiogenic drug therapy. The method is thus useful for diagnosing the hypertensive status of pregnant women, as well as patients undergoing anti-angiogenic treatment (e.g., chemotherapy).

Abstract translation: 提供了一种方法，其基于包括可溶性fms样酪氨酸激酶1（sFlt-1）水平在内的多种因子的测量，使受试者被诊断为患有各种高血压状态之一，包括先兆子痫 ），肥胖因子和任选的一种或多种另外的因子，其可以是生理参数或生物标志物。 该方法可用于确定与妊娠相关的高血压状态，或与抗血管生成药物治疗相关。 因此该方法用于诊断孕妇以及进行抗血管生成治疗的患者（例如化疗）的高血压状态。

公开(公告)号：WO2009155381A1

公开(公告)日：2009-12-23

申请号：PCT/US2009/047714

申请日：2009-06-17

Applicant: ABBOTT LABORATORIES ,  DATWYLER, Saul ,  HAWKSWORTH, David, J. ,  LAIRD, Don, M. ,  PUCCI, Dominick, L. ,  SOGIN, David, C. ,  TYNER, Joan, D. ,  ZIEMANN, Robert, N. ,  LESNIEWSKI, Richard, R. ,  MCKEEGAN, Evelyn, Mary

Inventor： DATWYLER, Saul ,  HAWKSWORTH, David, J. ,  LAIRD, Don, M. ,  PUCCI, Dominick, L. ,  SOGIN, David, C. ,  TYNER, Joan, D. ,  ZIEMANN, Robert, N. ,  LESNIEWSKI, Richard, R. ,  MCKEEGAN, Evelyn, Mary

IPC: G01N33/53

CPC classification number: G01N33/574 ,  G01N33/74 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present disclosure relates to, among other things, methods for determining whether a subject receiving treatment with a drug has obtained an efficacious blood level of the drug. Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from a disease will benefit from treatment with a drug, and the response of a subject receiving treatment (e.g., such as for cancer) by monitoring biomarkers of angiogenesis. In particular, the disclosure relates to P/GF-1 companion diagnostic methods and products.

Abstract translation: 本公开涉及用于确定接受药物治疗的受试者是否已经获得了药物有效血液水平的方法。 此外，本公开还涉及确定倾向于或患有疾病的受试者是否将受益于药物治疗的受试者以及通过监测血管发生生物标志物（例如癌症）的受试者的反应的方法 。 特别地，本公开涉及P / GF-1伴随诊断方法和产品。

公开(公告)号：WO2007059065B1

公开(公告)日：2007-09-13

申请号：PCT/US2006044059

申请日：2006-11-14

Applicant: ABBOTT LAB ,  SOGIN DAVID C ,  LAIRD DONALD M ,  YU ZHIGUANG ,  DOSS ROBERT C

Inventor： SOGIN DAVID C ,  LAIRD DONALD M ,  YU ZHIGUANG ,  DOSS ROBERT C

IPC: G01N33/566 ,  G01N33/50 ,  G01N33/53 ,  G01N33/68 ,  G01N33/74

CPC classification number: G01N33/566 ,  G01N33/689 ,  G01N33/74 ,  G01N2800/368

Abstract: Method of measuring the quantity of a first proteinaceous specific binding partner (sbp) in a biological sample comprising detecting the binding of the first proteinaceous sbp with a labeled second proteinaceous sbp, wherein neither the first or second sbp is an antibody or fragment thereof, which is preferably a method of determining the amount of sFlt-1, particularly free sFlt-1, and the amount of PlGF, particularly free PlGF, in a sample, which is preferably used in a method of predicting risk of preeclampsia comprising comparing free PlGF to free sFlt-1.

Abstract translation: 测量生物样品中第一蛋白质特异性结合配偶体（sbp）的量的方法，包括检测第一蛋白质sbp与标记的第二蛋白质sbp的结合，其中第一或第二sbp都不是抗体或其片段，其中 优选地是测定样品中sFlt-1的量，特别是游离的sFlt-1以及PlGF的量，特别是游离PlGF的量，其优选用于预测先兆子痫风险的方法中，其包括将游离PlGF与 免费sFlt-1。

公开(公告)号：WO2009155324A2

公开(公告)日：2009-12-23

申请号：PCT/US2009/047623

申请日：2009-06-17

Applicant: ABBOTT LABORATORIES ,  BROPHY, Susan, E. ,  CHI, Lianli ,  DATWYLER, Saul, A. ,  HAWKSWORTH, David, J. ,  LAIRD, Don, M. ,  MANOJ, Sharmila ,  PINKUS, Mary, S. ,  PUCCI, Dominick, L. ,  RAMSAY, Carol, S. ,  SOGIN, David, C. ,  TU, Bailin ,  TYNER, Joan, D. ,  YU, Zhiguang ,  ZIEMANN, Robert, N.

Inventor： BROPHY, Susan, E. ,  CHI, Lianli ,  DATWYLER, Saul, A. ,  HAWKSWORTH, David, J. ,  LAIRD, Don, M. ,  MANOJ, Sharmila ,  PINKUS, Mary, S. ,  PUCCI, Dominick, L. ,  RAMSAY, Carol, S. ,  SOGIN, David, C. ,  TU, Bailin ,  TYNER, Joan, D. ,  YU, Zhiguang ,  ZIEMANN, Robert, N.

IPC: C07K16/22 ,  C07K14/515 ,  C12N15/13 ,  C12N5/20

CPC classification number: C07K16/22 ,  C07K14/475 ,  C07K2317/92 ,  G01N33/74 ,  G01N2333/475

Abstract: The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.

Abstract translation: 本公开涉及糖基化和去糖基化的人PlGF-1，使用糖基化和去糖基化的人PlGF-1的方法，与人PlGF-1结合的抗体，使用抗体和人PlGF-1免疫测定和试剂盒的方法。

公开(公告)号：WO2007059065A3

公开(公告)日：2007-07-26

申请号：PCT/US2006044059

申请日：2006-11-14

Applicant: ABBOTT LAB ,  SOGIN DAVID C ,  LAIRD DONALD M ,  YU ZHIGUANG ,  DOSS ROBERT C

Inventor： SOGIN DAVID C ,  LAIRD DONALD M ,  YU ZHIGUANG ,  DOSS ROBERT C

IPC: G01N33/566 ,  G01N33/50 ,  G01N33/53 ,  G01N33/68 ,  G01N33/74

CPC classification number: G01N33/566 ,  G01N33/689 ,  G01N33/74 ,  G01N2800/368

Abstract: Method of measuring the quantity of a first proteinaceous specific binding partner (sbp) in a biological sample comprising detecting the binding of the first proteinaceous sbp with a labeled second proteinaceous sbp, wherein neither the first or second sbp is an antibody or fragment thereof, which is preferably a method of determining the amount of sFlt-1, particularly free sFlt-1, and the amount of PlGF, particularly free PlGF, in a sample, which is preferably used in a method of predicting risk of preeclampsia comprising comparing free PlGF to free sFlt-1.

Abstract translation: 测量生物样品中第一蛋白质特异性结合配偶体（sbp）的量的方法，包括检测第一蛋白质sbp与标记的第二蛋白质sbp的结合，其中第一或第二sbp都不是抗体或其片段，其 优选是确定优选用于预测先兆子痫风险的方法中的样品中sFlt-1，特别是游离sFlt-1的量和PlGF，尤其是游离PlGF的量的方法，其包括将游离PlGF与 免费sFlt-1。

公开(公告)号：WO2009155324A3

公开(公告)日：2010-02-18

申请号：PCT/US2009047623

申请日：2009-06-17

Applicant: ABBOTT LAB ,  BROPHY SUSAN E ,  CHI LIANLI ,  DATWYLER SAUL A ,  HAWKSWORTH DAVID J ,  LAIRD DON M ,  MANOJ SHARMILA ,  PINKUS MARY S ,  PUCCI DOMINICK L ,  RAMSAY CAROL S ,  SOGIN DAVID C ,  TU BAILIN ,  TYNER JOAN D ,  YU ZHIGUANG ,  ZIEMANN ROBERT N

Inventor： BROPHY SUSAN E ,  CHI LIANLI ,  DATWYLER SAUL A ,  HAWKSWORTH DAVID J ,  LAIRD DON M ,  MANOJ SHARMILA ,  PINKUS MARY S ,  PUCCI DOMINICK L ,  RAMSAY CAROL S ,  SOGIN DAVID C ,  TU BAILIN ,  TYNER JOAN D ,  YU ZHIGUANG ,  ZIEMANN ROBERT N

IPC: C07K16/22 ,  C07K14/515 ,  C12N5/20 ,  C12N15/13

CPC classification number: C07K16/22 ,  C07K14/475 ,  C07K2317/92 ,  G01N33/74 ,  G01N2333/475

Abstract: The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.

Abstract translation: 本公开涉及糖基化和去糖基化的人PlGF-1，使用糖基化和去糖基化的人PlGF-1的方法，与人PlGF-1结合的抗体，使用抗体和人PlGF-1免疫测定和试剂盒的方法。

公开(公告)号：WO2007059065A2

公开(公告)日：2007-05-24

申请号：PCT/US2006/044059

申请日：2006-11-14

Applicant: ABBOTT LABORATORIES ,  SOGIN, David, C. ,  LAIRD, Donald, M. ,  YU, Zhiguang ,  DOSS, Robert, C.

Inventor： SOGIN, David, C. ,  LAIRD, Donald, M. ,  YU, Zhiguang ,  DOSS, Robert, C.

IPC: G01N33/566 ,  G01N33/74 ,  G01N33/53 ,  G01N33/50

CPC classification number: G01N33/566 ,  G01N33/689 ,  G01N33/74 ,  G01N2800/368

Abstract: Method of measuring the quantity of a first proteinaceous specific binding partner (sbp) in a biological sample comprising detecting the binding of the first proteinaceous sbp with a labeled second proteinaceous sbp, wherein neither the first or second sbp is an antibody or fragment thereof, which is preferably a method of determining the amount of sFlt-1, particularly free sFlt-1, and the amount of PlGF, particularly free PlGF, in a sample, which is preferably used in a method of predicting risk of preeclampsia comprising comparing free PlGF to free sFlt-1.

Abstract translation: 测量生物样品中第一蛋白质特异性结合配偶体（sbp）的量的方法，包括检测第一蛋白质sbp与标记的第二蛋白质sbp的结合，其中第一或第二sbp 是抗体或其片段，其优选是测定样品中sFlt-1，特别是游离sFlt-1的量和PlGF，尤其是游离PlGF的量的方法，其优选用于预测 先兆子痫的风险包括将游离PlGF与游离sFlt-1进行比较。